IMMUNIC, INC. quarterly report, Q1 FY2014

Business context and reporting period

Entity discrepancy: The supplied filing is for Vital Therapies, Inc., not IMMUNIC, INC. Verify that this is the intended filing. It is an unaudited Form 10-Q for the three months ended March 31, 2014.

Vital Therapies was a development-stage biotherapeutics company developing the ELAD cell-based therapy for acute liver failure. It had no approved products and reported no revenue for the quarter.

Financial results and liquidity

Amounts below are in millions, except per-share data.

Cash and cash equivalents were $46.041 million at March 31, 2014, versus $38.186 million at December 31, 2013; working capital was $43.6 million. Investing activities used $0.853 million, including $0.809 million of property and equipment purchases. Financing activities provided $18.073 million, primarily from preferred stock issuance. The balance sheet reports no outstanding debt balance; preferred stock was presented outside stockholders’ equity, with a $156.366 million senior preferred liquidation preference.

Material changes and unusual items

• R&D expense rose $5.787 million year over year, primarily as Phase 3 trial activity expanded. G&A expense rose $1.163 million, including higher staffing, audit, legal, insurance and consulting costs.
• Net loss improved from the prior-year quarter partly because the company recorded a $1.128 million noncash gain from revaluing future purchase rights liabilities; Q1 2013 included a $4.434 million noncash revaluation expense.
• Common-stockholder loss includes $3.048 million of accretion to the redemption value of preferred stock and $0.022 million of deemed-dividend amortization.
• After quarter-end, the company completed an IPO and over-allotment, reporting estimated net proceeds of $52.4 million. Preferred stock converted into common stock and remaining future purchase rights terminated. The filing says cash, including IPO proceeds, was expected to fund operations into the second quarter of 2016, subject to spending and clinical-trial uncertainties.

Outlook, commentary and risks

• Management expected continued losses and rising R&D and G&A spending while advancing ELAD development. It anticipated no product revenue until late 2016 at the earliest.
• At May 27, 2014, VTI-208, a Phase 3 trial in alcohol-induced liver decompensation, had enrolled 111 subjects across 50 open sites. Enrollment in VTI-210 was expected to begin in Q2 2014; VTI-212 Phase 2 enrollment was expected in the second half of 2014.
• Key risks include trial enrollment, efficacy and safety outcomes, regulatory approval, manufacturing scale-up and supply continuity, and future financing needs. The FDA had raised concerns about VTI-208’s open-label design and potential confounding from differences in standard of care; prior trials had not demonstrated statistically significant improvement in their primary survival endpoints.
• The company disclosed previously identified material weaknesses in internal control over financial reporting and ongoing remediation efforts. Management nevertheless concluded disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2014.
• No material litigation was reported. The filing also describes potential reimbursement, product-liability, intellectual-property, supplier and international-operation risks.

Important facts for investors to verify

1. Confirm the intended issuer: the provided filing names Vital Therapies, Inc., while the request metadata names IMMUNIC, INC.
2. Check the IPO proceeds and cash runway assumptions, including whether later trial costs or enrollment rates change the stated funding horizon.
3. Track VTI-208, VTI-210 and VTI-212 enrollment, clinical outcomes, and regulatory feedback on trial design and evidence requirements.
4. Review progress remediating the disclosed material weaknesses and subsequent internal-control assessments.
5. Assess preferred-stock conversion, post-IPO share count and potential dilution; the filing reports 21,790,745 common shares outstanding as of May 27, 2014.